Business Wire

Adaptive Shield Secures Strategic Investment from Blackstone

25.7.2023 16:30:00 EEST | Business Wire | Press release

Share

Adaptive Shield, a leader in SaaS security, today announced a new investment from Blackstone Innovations Investments, Blackstone's strategic investment arm, bringing its total capital raised to $44M. This investment will be used to accelerate Adaptive Shield’s mission to protect companies as the number of SaaS applications used by enterprises has continued to grow rapidly. This growth is creating a new and complex mesh of business-critical applications that are increasingly being targeted by attackers.

“Thinking about where attackers are going next is key to growing a world-class cybersecurity program that protects our brand, reputation, investors, and intellectual property,” says Adam Fletcher, Chief Security Officer at Blackstone. “We have partnered with and are using Adaptive Shield to help us continuously monitor the security posture of business-critical SaaS applications used across Blackstone to further protect the firm from attackers. We believe in Adaptive Shield’s mission and are excited to support the company with our investment as they enter their next stage of growth.”

With Adaptive Shield, organizations can prevent, detect, and respond to identity-centric SaaS threats through Misconfiguration Management, SaaS-to-SaaS Access and Discovery, Identity & Access Governance, Device-to-SaaS User Risk Management, and Identity Threat Detection & Response (ITDR).

"Blackstone's investment demonstrates its success with our offering and underscores Adaptive Shield’s innovative capabilities as the only SaaS security platform to integrate with more than 130 applications that covers an expansive SaaS attack surface,” said Maor Bin, co-founder and CEO at Adaptive Shield. “With Blackstone's support, we will continue our trajectory for growth and expansion while keeping up with the constantly evolving threats.”

"At Blackstone, we have a dedicated team of cybersecurity professionals advising hundreds of our portfolio companies to further strengthen the cyber defense across the entire Blackstone ecosystem,” says Adam Mattina, Deputy Chief Security Officer and Head of Portfolio Cybersecurity at Blackstone. “We view the SaaS ecosystem as one of the top emerging attack vectors today, and our usage and investment in Adaptive Shield is highly strategic for the broader Blackstone portfolio as we collectively strive to stay ahead of such threats.”

To learn more about Adaptive Shield’s different use cases, please visit the use cases overview page.

About Adaptive Shield
Adaptive Shield, leader in SaaS Security, enables security teams to gain deep visibility and control over all business-critical SaaS applications and secure their entire SaaS stack through threat prevention, detection, and response. Founded by Maor Bin and Jony Shlomoff, Adaptive Shield works with many Fortune 500 enterprises and has been named Gartner® Cool VendorTM 2022. For more information, visit us at www.adaptive-shield.com or follow us on LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Doug Fraim, Guyer Group
doug@guyergroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Advances Operational Orchestration Vision with Agentic AI at Kinexions EMEA 202615.9.2026 14:00:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in AI-powered supply chain planning and orchestration, will bring together some of the world’s most innovative supply chain leaders at Kinexions EMEA 2026 from October 26-28. Building on the operational orchestration vision Kinaxis introduced earlier this year, the conference offers an inside look at how leading organizations are harnessing AI innovation and agentic capabilities to help supply chain leaders make better decisions, coordinate action across the business and drive measurable outcomes. From AI Potential to Operational Impact As organizations continue to invest heavily in AI, many struggle to translate intelligence into action - just 12% of supply chain leaders consider themselves AI leaders, despite widespread deployment of AI capabilities. Kinaxis CEO Razat Gaurav and Executive Vice President, EMEA, Fabienne Cêtre, will open the mainstage with an exploration of the market forces reshaping global supply chains and how operational orc

Cebreo Medical Receives CE Mark for NeuroBuds®, a Discreet In-Ear, Medical-Grade EEG Wearable for Extended Ambulatory Monitoring15.9.2026 14:00:00 EEST | Press release

Cebreo Medical today announced that its NeuroBuds® device has received CE marking, confirming conformity with applicable EU requirements. Unlike conventional EEG systems that require a technician-applied cap of electrodes, NeuroBuds is designed to be used unassisted by the patient at home, enabling multi-day and multi-night recordings in a patient's daily life environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914704547/en/ NeuroBuds(TM), EarEEG “With NeuroBuds, we can offer a discreet, unobtrusive solution that enables long-term, unassisted EEG monitoring for weeks, in patients’ own homes. The product has the potential to significantly reduce the cost of long-term EEG monitoring and strengthen treatment decisions compared with conventional brain monitoring.” — Rasmus Madsen, CEO, Cebreo Medical Designed to resemble a hearing aid, NeuroBuds is built to minimize the stigma and burden that typically limit complianc

Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 202615.9.2026 13:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP disease education initiative, to deepen understanding and increase recognition of TRD. The campaign explores the neurobiology of this distinct form of depression and is designed to help navigate care pathways for patients and providers. Change the Tune in TRD was developed to provide evidence-based education to U.S. HCPs on the longer, more persistent episodes associated with TRD, alongside cognitive and emotional patterns, including getting stuck in negative or repetitive ways of thinking, difficulty shifting perspective or navigating emotions, and feeling disconnected from pleasure or motivation1-8. While TRD originates as MDD, its burden and resistance to standard treatments distinguish it as a more complex condition. Compared to MDD, TRD patients experience almost 3x long

NIQ Launches Digital Purchase GeoAudiences Across Europe15.9.2026 13:00:00 EEST | Press release

NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the launch of Digital Purchase GeoAudiences across five European markets. The new solution extends NIQ’s geographic audience capabilities into digital-first categories including travel, automotive, technology, telecommunications and financial services. The launch expands NIQ’s GeoPurchase offering, which currently provides syndicated audiences across 13 international markets. Digital Purchase GeoAudiences address growing demand from advertisers for purchase-informed audience intelligence across a broader range of digital-first industries and shopping environments. By combining NIQ’s digital commerce intelligence with its GeoPurchase framework, the solution helps advertisers identify geographic areas showing stronger digital shopping activity. Marketers can use these signals to inform where they plan and prioritize media investment. “Marketers shouldn’t have to guess where demand is coming from before they invest,

QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases15.9.2026 13:00:00 EEST | Press release

QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaboration agreement with Eli Lilly and Company (“Lilly”) for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS). Lilly and QurCan will collaborate on multiple research programs focused on the development of PLNP-enabled genetic medicine therapeutics for CNS and PNS delivery. Through this collaboration, QurCan will be responsible for optimizing genetic medicine therapeutics using its TERP platform, and Lilly will be responsible for further research, clinical development, and commercialization of the selected programs. “This collaboration with Lilly represents a validation of our PLNP technology platform and its potential to address some of the most challenging delivery problems

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye